 Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome MDS Article outlines a new strategy to employ APVO436 for targeting both MDS clones and immunosuppressive myeloid-derived suppressor cells in high-risk adult MDS patients SEATTLE, WA ACCESSWIRE September 28, 2021 Aptevo Therapeutics Inc. Aptevo NASDAQ:APVO, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that the prestigious medical journal Frontiers in Aging, published a peer-reviewed article by Fatih Uckun, M.D., Ph.D., Chief Clinical Advisor at Aptevo who is coordinating the APVO436 clinical development program. 